1. Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids.
- Author
-
Crawford, Daniel K., Mullenders, Jasper, Pott, Johanna, Boj, Sylvia F., Landskroner-Eiger, Shira, and Goddeeris, Matthew M.
- Subjects
- *
ALLELES , *INTESTINES , *STOP codons , *ORGANOIDS , *NONSENSE mutation - Abstract
• Restricted protein production remains an unmet need in CF patients. • ELX-02 is a eukaryotic ribosomal selective glycoside that facilitates read-through of premature stop codons. • ELX-02 restored CFTR function in homozygous and heterozygous G542X organoids. • ELX-02 read-through increased G542X CFTR mRNA integrity in organoids. Promoting full-length protein production is a requisite step to address some of the remaining unmet medical need for those with Cystic Fibrosis (CF) nonsense alleles. ELX-02 promotes read-through of mRNA transcripts bearing nonsense mutations, including the most common CF nonsense allele G542X , in several different preclinical models including human bronchial epithelial cells. Here we evaluate ELX-02 mediated read-through using the CFTR-dependent Forskolin-induced swelling (FIS) assay across a selection of G542X genotype patient derived organoids (PDOs). CFTR functional restoration was evaluated in ELX-02 treated G542X homozygous and heterozygous PDOs in the CFTR-dependent FIS assay. CFTR mRNA abundance and integrity were evaluated by qPCR and Nanostring analysis while PDO protein was detected by capillary based size-exclusion chromatography. PDOs homozygous for G542X or heterozygous with a second minimally functional allele had significantly increased CFTR activity with ELX-02 in a dose-dependent fashion across a variety of forskolin induction concentrations. The functional increases are similar to those obtained with tezacaftor/ivacaftor in F508del homozygous PDOs. Increased CFTR C- and B-band protein was observed in accordance with increased function. In addition, ELX-02 treatment of a G542X/G542X PDO results in a 5-fold increase in CFTR mRNA compared with vehicle treated, resulting in normalization of CFTR mRNA as measured via Nanostring. These data with ELX-02 in PDOs are consistent with previous G542X model evaluations. These results also support the on-going clinical evaluation of ELX-02 as a read-through agent for CF caused by the G542X allele. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF